Aurinia Pharmaceuticals AUPH Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $298.21M+3.8% | $287.2M+269% | $77.84M+28.4% | $60.64M+52.2% | $39.85M+593% | ||
| $19.41M-0.2% | $19.45M0.0% | $19.45M-0.1% | $19.48M+0.1% | $19.45M0.0% | ||
| $17.22M+17.3% | $14.68M-13.1% | $16.9M-12.5% | $19.3M-14.0% | $22.45M-28.9% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.14M-116% | ||
| $1.94M+872% | $200K+104% | -$5.42M— | —— | —— | ||
| —— | —— | —— | $11.58M+14.3% | $10.13M+75.1% | ||
| —— | —— | —— | —— | —— | ||
| -$821K-2.4% | -$802K-0.3% | -$800K-2.6% | -$780K-2.1% | -$764K-1.9% | ||
| $9.08M+75.7% | $5.17M+194% | -$5.5M-137% | $14.83M— | —— | ||
| $166.92M+23.0% | $135.66M+13.0% | $120.1M+29.6% | $92.68M+44.2% | $64.29M+44.8% | ||
| —— | —— | —— | —— | —— | ||
| $87.4M-11.0% | $98.16M-18.2% | $119.96M+7.8% | $111.29M+48.7% | $74.86M+86.0% | ||
| —— | —— | —— | —— | —— | ||
| $16.79M+5.5% | $15.91M+3.0% | $15.45M+3.3% | $14.96M+1.4% | $14.76M0.0% | ||
| $15.41M+57.8% | $9.76M+1.3% | $9.64M+2.1% | $9.45M-1.3% | $9.57M+56.0% | ||
| -$110.46M-4.1% | -$106.11M+16.6% | -$127.27M-6.5% | -$119.5M-43.3% | -$83.38M-69.8% | ||
| —— | —— | —— | $19.6M+895% | $1.97M-94.3% | ||
| $4.17M+35.0% | $3.09M-19.0% | $3.82M+113% | $1.79M-26.3% | $2.43M+11.3% | ||
| $9.84M-3.3% | $10.18M-6.0% | $10.82M-6.9% | $11.62M-4.6% | $12.18M-4.3% | ||
| -$7.46M+23.0% | -$9.69M-135% | -$4.13M— | —— | —— | ||
| —— | —— | —— | —— | -$2.14M-116% | ||
| -$821K-2.4% | -$802K-0.3% | -$800K-2.6% | -$780K-2.1% | -$764K-1.9% | ||
| —— | —— | —— | —— | —— | ||
| $1.94M+872% | $200K+104% | -$5.42M— | —— | —— | ||
| $274K+8.7% | $252K+6.8% | $236K-7.8% | $256K-10.5% | $286K+1.8% | ||
| $16.79M+5.5% | $15.91M+3.0% | $15.45M+3.3% | $14.96M+1.4% | $14.76M0.0% | ||
| —— | —— | —— | $11.58M+14.3% | $10.13M+75.1% | ||
| -$821K-2.4% | -$802K-0.3% | -$800K-2.6% | -$780K-2.1% | -$764K-1.9% | ||
| —— | $3.77M+33.3% | $2.83M+50.0% | $1.89M+100% | $943.25K— | ||
| $4.17M+35.0% | $3.09M-19.0% | $3.82M+113% | $1.79M-26.3% | $2.43M+11.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aurinia Pharmaceuticals generate?
- Aurinia Pharmaceuticals (AUPH) generated $166.9M in operating cash flow over the trailing twelve months.
- Where does Aurinia Pharmaceuticals's cash flow data come from?
- Every line is extracted from Aurinia Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
